Miguel Castresana‑Aguirre

The tumour microenvironment influences long-term tamoxifen benefit in postmenopausal ER+/HER2− breast cancer patients: a secondary analysis of the randomised Stockholm Tamoxifen (STO-3) trial

Abstract Background The tumour microenvironment (TME) influences breast cancer progression and treatment response. We investigated whether TME composition predicts tamoxifen benefit in postmenopausal women with oestrogen receptor-positive, HER2-negative (ER+HER2-) breast cancer....